Evidence map›Paper›PMID 31671430›Full record

ArticleNeuroendocrinology2020

Chronic Testosterone Deprivation Sensitizes the Middle-Aged Rat Brain to Damaging Effects of Testosterone Replacement.

Charity Smith, Jo Contreras-Garza, Rebecca L Cunningham, Jessica M Wong, Philip H Vann, Daniel Metzger, Ella Kasanga, Anthony Oppong-Gyebi, Nathalie Sumien, Derek A Schreihofer

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuroendocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Charity SmithDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Jo Contreras-GarzaDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Rebecca L CunninghamInstitute for Healthy Aging, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Jessica M WongDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Philip H VannDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Daniel MetzgerDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Ella KasangaDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Anthony Oppong-GyebiDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Nathalie SumienDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Derek A SchreihoferDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas, USA, derek.schreihofer@unthsc.edu.
University of North Texas · USUniversity of North Texas Health Science Center · US

Funding

Pilot study on the risks of testosterone replacement to the brainR03AG049255 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI CUNNINGHAM, REBECCA L, SCHREIHOFER, DEREK A · 2015 to 2016
$146k
NIA NIH HHS R03 AG049255
6 · The paper itself

Abstract

introductionAn increasing number of middle-aged men are being screened for low testosterone levels and the number of prescriptions for various forms of testosterone replacement therapy (TRT) has increased dramatically over the last 10 years. However, the safety of TRT has come into question with some studies suggesting increased morbidity and mortality.

objectiveBecause the benefits of estrogen replacement in postmenopausal women and ovariectomized rodents are lost if there is an extended delay between estrogen loss and replacement, we hypothesized that TRT may also be sensitive to delayed replacement.

methodsWe compared the effects of testosterone replacement after short-term (2 weeks) and long-term testosterone deprivation (LTTD; 10 weeks) in middle-aged male rats on cerebral ischemia, oxidative stress, and cognitive function. We hypothesized that LTTD would increase oxidative stress levels and abrogate the beneficial effects of TRT.

resultsHypogonadism itself and TRT after short-term castration did not affect stroke outcome compared to intact rats. However, after long-term hypogonadism in middle-aged male Fischer 344 rats, TRT exacerbated the detrimental behavioral effects of experimental focal cerebral ischemia, whereas this detrimental effect was prevented by administration of the free-radical scavenger tempol, suggesting that TRT exacerbates oxidative stress. In contrast, TRT improved cognitive performance in non-stroked rats regardless of the length of hypogonadism. In the Morris water maze, peripheral oxidative stress was highly associated with decreased cognitive ability.

conclusionsTaken together, these data suggest that TRT after long-term hypogonadism can exacerbate functional recovery after focal cerebral ischemia, but in the absence of injury can enhance cognition. Both of these effects are modulated by oxidative stress levels.

Indexed as

AgingBrain IschemiaCognitive DysfunctionHypogonadismOxidative StressAnimalsCastrationDisease Models, AnimalHormone Replacement TherapyMaleMaze LearningRatsRats, Inbred F344TestosteroneTime FactorsTestosteroneAgingCognitionHormone replacementStroke

Identifiers

PMID31671430
PMCPMC12786679
OpenAlexW2988629431

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.